Back to search

Peptide record

TPDB10894

Pardaxin-6 Antibacterial Anticancer Toxicity standard

27 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB10894

Peptide_Name

Pardaxin-6

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

GFFALIPKIISSPLFKTLLSAVGSALS

FASTA

>TPDB10894|Antibacterial;Anticancer;Toxicity|length=27
GFFALIPKIISSPLFKTLLSAVGSALS

Formula C134H217N29O34

Absent Amino Acids RNDCEQHMWY

Common Amino Acids LS

Mass 2778.37

PI 10.60

Basic Residues 2

Acidic Residues 0

Hydrophobic Residues 15

Net Charge +2

Boman Index -3.87

Hydrophobicity 1.259

Aliphatic Index 137.41

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 6

number

Amino Acid Distribution

A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 5 K: 2 M: 0 F: 3 P: 2 S: 5 T: 1 W: 0 Y: 0 V: 1

Length

Formula

C134H217N29O34

Mass

2778.37

10.60

Net Charge

Boman Index

-3.87

Hydrophobicity

1.259

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Epinephelus nebulosus

Evidence 1 Activity

Activity

Activity Raw

70 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

60 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Raw

4 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Raw

5 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Raw

1 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 6 Activity

Activity

Activity Raw

78 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 7 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 8 Activity

Activity

Activity Raw

10 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 9 Activity

Activity

Activity Raw

10 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 10 Activity

Activity

Activity Raw

5 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 11 Activity

Activity

Activity Raw

82 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 12 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 13 Activity

Activity

Activity Raw

18 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 14 Activity

Activity

Activity Raw

4 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 15 Activity

Activity

Activity Raw

10 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 16 Activity

Activity

Activity Raw

90 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 17 Activity

Activity

Activity Raw

82 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 18 Activity

Activity

Activity Raw

18 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 19 Activity

Activity

Activity Raw

18 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 20 Activity

Activity

Activity Raw

18 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 21 Activity

Activity

Activity Raw

80 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 22 Activity

Activity

Activity Raw

85 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 23 Activity

Activity

Activity Raw

45 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 24 Activity

Activity

Activity Raw

30 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 25 Activity

Activity

Activity Raw

25 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 26 Activity

Activity

Activity Raw

84 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 27 Activity

Activity

Activity Raw

84% Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 28 Activity

Activity

Activity Raw

48 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 29 Activity

Activity

Activity Raw

30 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 30 Activity

Activity

Activity Raw

35 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 31 Activity

Activity

Activity Raw

90 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 32 Activity

Activity

Activity Raw

85 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 33 Activity

Activity

Activity Raw

30 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 34 Activity

Activity

Activity Raw

35 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 35 Activity

Activity

Activity Raw

15 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 36 Activity

Activity

Activity Raw

90 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 37 Activity

Activity

Activity Raw

90 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 38 Activity

Activity

Activity Raw

20 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 39 Activity

Activity

Activity Raw

1 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 40 Activity

Activity

Activity Raw

10 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 41 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 100 | µg/mL | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Truncated antimicrobial peptides from marine organisms retain anticancer activity and antibacterial activity against multidrug-resistant Staphylococcus aureus. | Peptides | 2013

Evidence 42 Activity

Activity

Activity Endpoint % Hemolysis

Detail Source Activity Toxicity

Activity Measurement 8 %

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.23598079] 8% hemolysis at 12.5 mg/L , 29% hemolysis at 25 mg/L , 38% hemolysis at 50 mg/L , 57.5% hemolysis at 100 mg/L , 99% hemolysis at 200 mg/L , 98% hemolysis at 400 mg/L against sheep red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Peptides. 2013 Jun 44:139-48. doi: 10.1016/j.peptides.2013.04.004.